Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2019)-Reference-Cited by-同舟云学术

Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2019)

Published:2019-04-12 Issue:S1 Volume:131 Page:27-38
ISSN:0043-5325
Container-title:Wiener klinische Wochenschrift
language:de
Short-container-title:Wien Klin Wochenschr

Author:

Clodi Martin,Abrahamian Heidemarie,Brath Helmut,Brix Johanna,Drexel Heinz,Fasching Peter,Föger Bernhard,Francesconi Claudia,Fröhlich-Reiterer Elke,Harreiter Jürgen,Hofer Sabine E.,Hoppichler Friedrich,Huber Joakim,Kaser Susanne,Kautzky-Willer Alexandra,Lechleitner Monika,Ludvik Bernhard,Luger Anton,Mader Julia K.,Paulweber Bernhard,Pieber Thomas,Prager Rudolf,Rami-Merhar Birgit,Resl Michael,Riedl Michaela,Roden Michael,Saely Christoph H.,Schelkshorn Christian,Schernthaner Guntram,Sourij Harald,Stechemesser Lars,Stingl Harald,Toplak Hermann,Wascher Thomas C.,Weitgasser Raimund,Winhofer-Stöckl Yvonne,Zlamal-Fortunat Sandra

Funder

Johannes Kepler University Linz

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00508-019-1471-z.pdf

Reference27 articles.

1. Davies MJ, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461–98.

2. Peters AL, et al. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015;38(9):1687–93.

3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998. 352(9131): p. 837–53.